Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.58 and traded as high as $0.69. Sangamo Therapeutics shares last traded at $0.64, with a volume of 3,959,993 shares.
Analysts Set New Price Targets
A number of equities research analysts have commented on the stock. Wall Street Zen upgraded shares of Sangamo Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, September 4th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Sangamo Therapeutics in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Sangamo Therapeutics presently has an average rating of "Hold" and an average target price of $4.50.
View Our Latest Stock Report on Sangamo Therapeutics
Sangamo Therapeutics Stock Performance
The business's fifty day simple moving average is $0.59 and its 200-day simple moving average is $0.58. The firm has a market capitalization of $194.45 million, a PE ratio of -2.22 and a beta of 1.22.
Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. The company had revenue of $18.31 million for the quarter, compared to analysts' expectations of $31.68 million. Sell-side analysts expect that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of SGMO. Wasatch Advisors LP grew its holdings in shares of Sangamo Therapeutics by 17.7% in the second quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company's stock valued at $4,376,000 after purchasing an additional 1,215,653 shares in the last quarter. GSA Capital Partners LLP grew its holdings in shares of Sangamo Therapeutics by 2,962.2% in the first quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company's stock valued at $634,000 after purchasing an additional 934,649 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Sangamo Therapeutics by 74.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company's stock valued at $851,000 after purchasing an additional 555,323 shares in the last quarter. Luminus Management LLC purchased a new position in shares of Sangamo Therapeutics in the third quarter valued at $168,000. Finally, Invesco Ltd. boosted its stake in Sangamo Therapeutics by 82.8% during the first quarter. Invesco Ltd. now owns 483,894 shares of the biopharmaceutical company's stock worth $317,000 after buying an additional 219,253 shares during the period. 56.92% of the stock is owned by hedge funds and other institutional investors.
About Sangamo Therapeutics
(
Get Free Report)
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sangamo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sangamo Therapeutics wasn't on the list.
While Sangamo Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
